Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct 2;11(11):004894.
doi: 10.12890/2024_004894. eCollection 2024.

Infliximab in the Treatment of a Giant Coronary Aneurysm in Behçet's Disease

Affiliations

Infliximab in the Treatment of a Giant Coronary Aneurysm in Behçet's Disease

Salma Boustani et al. Eur J Case Rep Intern Med. .

Abstract

Background: Behçet's disease (BD) is a rare, multisystemic inflammatory disorder with a diverse range of manifestations, primarily affecting the mucocutaneous and ocular systems. While vascular involvement is less frequent it can be severe, with coronary aneurysms being particularly rare.

Case description: We report a 28-year-old male with BD who developed a giant anterior interventricular artery aneurysm. The patient, initially managed with azathioprine and colchicine, presented with acute chest pain and elevated cardiac markers. Imaging revealed a coronary aneurysm measuring 5.03 cm. Due to the inflammatory nature of the aneurysm surgical intervention was initially deferred, and the patient was treated with corticosteroids and cyclophosphamide. Despite these treatments, recurrent symptoms prompted the initiation of infliximab therapy. Administered at 5 mg/kg at weeks 0, 2 and 6, with subsequent doses every two months, infliximab led to a significant reduction in aneurysm size to 3.73 cm.

Conclusion: This case highlights the effectiveness of infliximab in managing giant coronary aneurysms associated with BD, demonstrating its potential as a treatment option for severe vascular complications in BD. The substantial reduction in aneurysm size following infliximab therapy underscores the need for further investigation into its role in treating such rare but serious manifestations of BD.

Learning points: A giant coronary aneurysm is a rare complication of Behçet's disease.Infliximab effectively reduced the aneurysm size.Imaging shows a substantial decrease in aneurysm size after infliximab treatment.

Keywords: Behçet’s disease; cardiovascular complications; giant coronary aneurysm; infliximab.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interests: The Authors declare that there are no competing interests.

Figures

Figure 1
Figure 1
Thoraco-abdominal CT showing a giant coronary aneurysm in the anterior interventricular artery before infliximab treatment, measuring 5.03 cm.
Figure 2
Figure 2
Thoraco-abdominal CT showing a significant reduction in the coronary aneurysm in the anterior interventricular artery after infliximab treatment, measuring approximately 3.73 cm.

References

    1. Leccese P, Yazici Y, Olivieri I. Behcet’s syndrome in nonendemic regions. Curr Opin Rheumatol. 2017;29:12–16. - PubMed
    1. Sarica-Kucukoglu R, Akdag-Kose A, Kayabali M, Yazganoglu KD, Disci R, Erzengin D, et al. Vascular involvement in Behçet’s disease: a retrospective analysis of 2,319 cases. Int J Dermatol. 2006;45:919–921. - PubMed
    1. Criteria for diagnosis of Behcet’s disease. International Study Group for Behcet’s Disease. Lancet. 1990;335:1078–1080. - PubMed
    1. Schiff S, Moffatt R, Mandel WJ, Rubin SA. Acute myocardial infarction and recurrent ventricular arrhythmias in Behçet’s syndrome. Am Heart J. 1982;103:438–440. - PubMed
    1. Kariyanna PT, Shah P, Jayarangaiah A, Chowdhury YS, Lazaro D. Acute coronary syndrome in Behcet’s syndrome: a systematic review. Eur J Rheumatol. 2021;8:31–35. - PMC - PubMed

LinkOut - more resources